News
CPhI Japan to be postponed on request of event attendees
CPhI Japan – organised by Informa Markets – announces that the event will be postponed until a new date later in the year after extensive consultation with key stakeholders and consideration of all alternatives. The event, which was due...
Clinical Trials
IQVIA Launches Avacare Clinical Research Network to Increase Patients Clinical and Research Options
IQVIA™ (NYSE: IQV), a leader in human data science, announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools...
Drug Research
Novartis and DNDi to jointly develop a new oral drug to treat visceral leishmaniasis
Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis.
LXE408 is an oral treatment for this parasitic disease, which...
News
Bicycle Therapeutics and Genentech to Develop and Commercialize Bicycle based Immuno oncology Therapies
Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced that it has entered into a strategic collaboration agreement with Genentech, a member of the Roche...
Clinical Trials
Biocons Insulin Manufacturing Facility in Malaysia Completes U.S. FDA Inspection
This is to inform you that the U.S. FDA conducted a pre-approval inspection (PAI) of our subsidiary, Biocon Sdn. Bhd’s Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between Feb 10 and Feb 21, 2020.
At the conclusion of...
News
RedHill Biopharma Acquires Rights to Movantik from AstraZeneca
RedHill Biopharma Ltd. , a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal (“GI”) diseases, announced that it is acquiring the global rights to Movantik® (naloxegol)1, excluding Europe, Canada...
News
ICON Acquires European CRO MedPass International
ICON plc, a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, announced that it has acquired MedPass International, the leading European medical device CRO, regulatory and reimbursement consultancy, that specialises in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















